Compare Stocks: NAMS, ELAN, ARWR, and AXSM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.00 +0.4%	$79.04	$15.01 ▼ $95.49	$11.97B	1.27	2.46 million shs	6,210 shs
AXSM Axsome Therapeutics	$217.99	$239.21	$96.09 ▼ $260.19	$11.22B	0.65	763,277 shs	586 shs
ELAN Elanco Animal Health	$26.52 +0.6%	$24.55	$13.75 ▼ $27.72	$13.25B	1.68	5.28 million shs	11,557 shs
NAMS NewAmsterdam Pharma	$27.79	$32.16	$21.14 ▼ $42.21	$3.25B	0.1	932,963 shs	956,633 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-1.11%	+0.79%	+13.15%	+431.39%
AXSM Axsome Therapeutics	0.00%	-9.55%	-10.77%	+5.55%	+111.60%
ELAN Elanco Animal Health	0.00%	+6.12%	+5.95%	+17.22%	+91.48%
NAMS NewAmsterdam Pharma	0.00%	-6.24%	-20.21%	-2.25%	+30.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.00 +0.4%	$79.04	$15.01 ▼ $95.49	$11.97B	1.27	2.46 million shs	6,210 shs
AXSM Axsome Therapeutics	$217.99	$239.21	$96.09 ▼ $260.19	$11.22B	0.65	763,277 shs	586 shs
ELAN Elanco Animal Health	$26.52 +0.6%	$24.55	$13.75 ▼ $27.72	$13.25B	1.68	5.28 million shs	11,557 shs
NAMS NewAmsterdam Pharma	$27.79	$32.16	$21.14 ▼ $42.21	$3.25B	0.1	932,963 shs	956,633 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-1.11%	+0.79%	+13.15%	+431.39%
AXSM Axsome Therapeutics	0.00%	-9.55%	-10.77%	+5.55%	+111.60%
ELAN Elanco Animal Health	0.00%	+6.12%	+5.95%	+17.22%	+91.48%
NAMS NewAmsterdam Pharma	0.00%	-6.24%	-20.21%	-2.25%	+30.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$96.92	14.02% Upside
AXSM Axsome Therapeutics	2.91	Moderate Buy	$261.29	19.86% Upside
ELAN Elanco Animal Health	2.77	Moderate Buy	$28.73	8.32% Upside
NAMS NewAmsterdam Pharma	2.93	Moderate Buy	$49.42	77.82% Upside

Current Analyst Ratings Breakdown

Latest NAMS, ELAN, ARWR, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$310.00 ➝ $306.00
7/30/2026	ARWR Arrowhead Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$101.00 ➝ $123.00
7/27/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$100.00 ➝ $115.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $120.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00 ➝ $126.00
7/22/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $115.00
7/22/2026	ELAN Elanco Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
7/20/2026	NAMS NewAmsterdam Pharma	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$58.00
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$310.00
7/20/2026	NAMS NewAmsterdam Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.43	$0.12 per share	708.96	$3.64 per share	23.35
AXSM Axsome Therapeutics	$638.50M	17.57	N/A	N/A	$1.75 per share	124.57
ELAN Elanco Animal Health	$4.89B	2.71	$2.33 per share	11.36	$13.18 per share	2.01
NAMS NewAmsterdam Pharma	$22.50M	144.38	N/A	N/A	$5.97 per share	4.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.15	N/A	N/A	N/A	-48.38%	-55.09%	-18.13%	8/4/2026 (Estimated)
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	53.69	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.50	N/A	21.39	1.72	-4.95%	7.42%	3.66%	8/5/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$1.79	N/A	N/A	N/A	-943.23%	-26.49%	-24.37%	8/5/2026 (Estimated)

Latest NAMS, ELAN, ARWR, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	N/A	N/A	N/A	$221.11 million	N/A
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	N/A	N/A	N/A	$1.31 billion	N/A
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4726	N/A	N/A	N/A	$1.88 million	N/A
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.28	N/A	N/A	N/A	$44.17 million	N/A
5/7/2026	Q2 2026	ARWR Arrowhead Pharmaceuticals	-$1.0950	-$0.93	+$0.1650	-$0.93	$73.84 million	$73.74 million
5/7/2026	Q1 2026	NAMS NewAmsterdam Pharma	-$0.46	-$0.40	+$0.06	-$0.40	$1.75 million	$3.04 million
5/6/2026	Q1 2026	ELAN Elanco Animal Health	$0.34	$0.40	+$0.06	$0.11	$1.28 billion	$1.37 billion
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.41	6.23	6.23
AXSM Axsome Therapeutics	2.27	1.39	1.32
ELAN Elanco Animal Health	0.60	2.16	1.12
NAMS NewAmsterdam Pharma	N/A	9.76	9.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
AXSM Axsome Therapeutics	81.49%
ELAN Elanco Animal Health	97.48%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
AXSM Axsome Therapeutics	20.60%
ELAN Elanco Animal Health	1.14%
NAMS NewAmsterdam Pharma	12.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
ELAN Elanco Animal Health	9,400	499.45 million	493.76 million	Optionable
NAMS NewAmsterdam Pharma	4	116.90 million	102.01 million	Optionable

NAMS, ELAN, ARWR, and AXSM Headlines

Recent News About These Companies

RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)

August 2 at 8:17 AM | theglobeandmail.com

Janus Henderson Group PLC Sells 82,739 Shares of NewAmsterdam Pharma Company N.V. $NAMS

August 2 at 5:43 AM | marketbeat.com

NewAmsterdam Pharma Company N.V. $NAMS Stake Boosted by Stempoint Capital LP

July 30, 2026 | marketbeat.com

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

July 29, 2026 | markets.businessinsider.com

NewAmsterdam Pharma (NAMS) Projected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $49.42 Average Price Target from Analysts

July 29, 2026 | americanbankingnews.com

Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

July 28, 2026 | marketbeat.com

Eversept Partners LP Sells 135,063 Shares of NewAmsterdam Pharma Company N.V. $NAMS

July 28, 2026 | marketbeat.com

Maverick Capital Ltd. Has $69.99 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

July 28, 2026 | marketbeat.com

NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)

July 26, 2026 | prnewswire.com

NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)

July 25, 2026 | prnewswire.com

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus ...

July 24, 2026 | aol.comA

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

July 24, 2026 | globenewswire.com

Walleye Capital LLC Sells 37,827 Shares of NewAmsterdam Pharma Company N.V. $NAMS

July 24, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 24, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. $NAMS Stake Cut by Decheng Capital LLC

July 23, 2026 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded by BMO Capital Markets to "Strong-Buy" Rating

July 22, 2026 | marketbeat.com

SEB Asset Management AB Buys New Holdings in NewAmsterdam Pharma Company N.V. $NAMS

July 22, 2026 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 5.6% - Time to Sell?

July 20, 2026 | marketbeat.com

Jennison Associates LLC Cuts Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

July 20, 2026 | marketbeat.com

Pictet Asset Management Holding SA Lowers Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

July 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NAMS, ELAN, ARWR, and AXSM Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$85.00 +0.35 (+0.41%)

As of 09:00 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Axsome Therapeutics NASDAQ:AXSM

$217.99 0.00 (0.00%)

As of 08:55 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health NYSE:ELAN

$26.52 +0.15 (+0.57%)

As of 08:59 AM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

NewAmsterdam Pharma NASDAQ:NAMS

$27.79 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$27.76 -0.04 (-0.13%)

As of 07/31/2026 07:34 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAMS, ELAN, ARWR, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAMS, ELAN, ARWR, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAMS, ELAN, ARWR, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NAMS, ELAN, ARWR, and AXSM Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Axsome Therapeutics NASDAQ:AXSM

Elanco Animal Health NYSE:ELAN

NewAmsterdam Pharma NASDAQ:NAMS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NAMS, ELAN, ARWR, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NAMS, ELAN, ARWR, and AXSM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NAMS, ELAN, ARWR, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NAMS, ELAN, ARWR, and AXSM Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Axsome Therapeutics NASDAQ:AXSM

Elanco Animal Health NYSE:ELAN

NewAmsterdam Pharma NASDAQ:NAMS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools